Study will evaluate the safety, tolerability and pharmacokinetics (PK) of OCT-980 in healthy volunteers
Initiation of the study marks Octant’s transition to a clinical-stage company
Presenters: Nathan Abell, Conor Howard, Erin Thompson, Diane Dickel, EricEric Jones, Beatriz Osuna, Nathan Lubock, Leon Chan, Jonathan Asfaha , Dean Artis, James Fraser, Deborah Marks